Will the FDA approve a new treatment for Long COVID based on the findings of the Iwasaki study by December 31, 2024?

Will NIH significantly increase Long COVID research funding by end of 2024?

Will the FDA approve a new treatment for Long COVID targeting T cell activation by end of 2024?

Will the CDC introduce new Long COVID treatment guidelines based on the Iwasaki study by December 31, 2024?

What will be the primary symptom targeted by new Long COVID treatments developed based on the Iwasaki study by December 31, 2024?

What will be the major funding source for new Long COVID research initiatives based on the Iwasaki study by December 31, 2024?

Will Akiko Iwasaki or her colleagues publish a follow-up study on Long COVID by December 31, 2024?

What will follow-up studies identify as the primary location of persistent SARS-CoV-2 in Long COVID patients by December 31, 2024?

What will be the primary focus of the most significant Long COVID study published in 2024?

Will a new treatment for persistent viral RNA in Long COVID be announced by end of 2024?

Which pharmaceutical company will first announce a new treatment for persistent viral RNA in Long COVID by end of 2024?

Which research institution will publish the most cited paper on Long COVID in 2024?